Funding rounds
Every row was found by Firecrawl search and extracted with a schema, with the articles behind it one click away. A check mark means its sources confirmed it.
Every row was found by Firecrawl search and extracted with a schema, with the articles behind it one click away. A check mark means its sources confirmed it.
| Expand | Company | Round | |||
|---|---|---|---|---|---|
An AI-native operating system for institutional capital | Series A Verified against 1 of 34 sources | $10M | 2026-11-04 6d ago | No recent discussion | |
A company that operates the drawing management system Zmeen | Series D Verified against 4 of 8 sources | $28.8M | 2026-11-04 6d ago | No recent discussion | |
A SaaS startup for the manufacturing industry | Series D Verified against 1 of 25 sources | $28.8M | 2026-11-04 6d ago | No recent discussion | |
A biotechnology company developing placenta-targeted mRNA medicines for serious maternal and fetal disorders | Seed Developing, 9 sources | not stated | 2026-11-04 6d ago | No recent discussion | |
App store for AI | Seed Developing, 13 sources | $5M | 2026-11-04 6d ago | No recent discussion | |
A leading consulting and advisory firm serving the North American utility and energy industry | Growth Developing, 6 sources | not stated | 2026-11-04 6d ago | No recent discussion | |
Brava Security offers a Security Operations Platform that enhances threat detection and response capabilities for security teams. | Seed Verified against 4 of 36 sources | $15M | 2026-11-04 6d ago | No recent discussion | |
Boyi Group specializes in the development and production of biological purification materials and associated services for the life sciences sector. | Series B Verified against 2 sources | $15.0M | 2026-11-04 6d ago | No recent discussion | |
A human cell programming company developing technology to produce consistent, scalable human cell models for drug discovery, disease research, functional genomics and toxicology. | Series D Verified against 4 of 9 sources | $25M | 2026-11-04 6d ago | No recent discussion | |
A BioTech company developing an oral device to deliver therapeutics | Funding round Developing, 7 sources | $22.5M | 2026-11-04 6d ago | No recent discussion | |
Atmospheric AI offers an AI-powered platform that models raw material supply chains to optimize procurement decisions for businesses. | Seed Verified against 4 of 11 sources | $10M | 2026-11-04 6d ago | No recent discussion | |
Arcade is the AI video platform for marketing teams. | Series A Developing, 1 source | $14M | 2026-11-04 6d ago | No recent discussion | |
altM specializes in engineering waste biomass and industrial bio-residue into sustainable chemicals and materials. | Series A Verified against 4 of 80 sources | $10.3M | 2026-11-04 6d ago | No recent discussion | |
A robotics company that designs and deploys autonomous mobile robots and fleet-management software | Seed Verified against 4 of 23 sources | $7.0M | 2026-11-04 6d ago | No recent discussion | |
Wegofair offers AI-based online brand protection services that monitor and block counterfeit products in various markets worldwide. | Pre-A Verified against 4 of 9 sources | $760K | 2026-11-03 Nov 3 | No recent discussion | |
A Trondheim, Norway-based biotech company providing a platform for studying immune activity, treatment responses and disease mechanisms in real time | Seed Verified against 1 of 17 sources | $5M | 2026-11-03 Nov 3 | No recent discussion | |
A provider of a catalyst platform for CO2-to-chemicals innovation | Funding round Verified against 4 of 8 sources | $2.9M | 2026-11-03 Nov 3 | No recent discussion | |
Aerospace startup developing an electric nine-seater aircraft for zero-emission regional flights | Series A Verified against 4 of 10 sources | $33.7M | 2026-11-03 Nov 3 | No recent discussion | |
Tumbleweed offers microgravity research services and payload shipping to Low-Earth Orbit for various research and commercial applications. | Seed Verified against 4 of 19 sources | $7.7M | 2026-11-03 Nov 3 | No recent discussion | |
A clinical-stage biotechnology company developing precision therapies for inherited channelopathies, cardiometabolic diseases and cardiomyopathies. | Series B Verified against 3 sources | $30M | 2026-11-03 Nov 3 | No recent discussion |
Records are extracted automatically from public reporting and link to their sources. They can contain errors. Report an error